SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

NEW YORK, April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980

The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately. Notably, although Zymeworks indicated that it had appointed current President and Chief Executive Officer Kenneth Galbraith as Interim CFO and had initiated a search for a new CFO, the Company failed to provide any reasoning for Astle's removal as SVP and CFO. 

On this news, Zymeworks's stock price fell $0.64 per share, or 6.08%, to close at $9.88 per share on April 1, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zymeworks-inc---zyme-302121461.html

SOURCE Pomerantz LLP